External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial

被引：0
|
作者：
Paganelli, G. [1 ]
Rossetti, C. [2 ]
Aglietta, M. [3 ]
Messina, C. [4 ]
Versari, A. [5 ]
Michalski, J. M. [6 ]
O'Sullivan, J. M. [7 ]
Parker, C. [8 ,9 ]
Garcia-Vargas, J. E. [10 ]
Sartor, A. [11 ]
Finkelstein, S. E. [12 ]
机构：
[1] IRCCS Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, IT, Italy
[2] AO Osped Niguarda Ca Granda, Milan, Italy
[3] IRCCS Candiolo, Candiolo, TO, Italy
[4] AO Papa Giovanni XXIII, Bergamo, IT, Italy
[5] IRCCS AO Arcispedale S Maria Nuova, Reggio Emilia, IT, Italy
[6] Washington Univ, Sch Med, St Louis, MO USA
[7] Queens Univ, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland
[8] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[9] Inst Canc Res, Sutton, Surrey, England
[10] Bayer HealthCare, Whippany, NJ USA
[11] Tulane Canc Ctr, New Orleans, LA USA
[12] 21st Century Oncol, Scottsdale, AZ USA
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
F31
引用
收藏
页码：62 / 62
页数：1
相关论文
共 50 条
  • [31] 3-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.
    Parker, Chris
    Vogelzang, Nicholas J.
    Sartor, A. Oliver
    Coleman, Robert E.
    Skjorestad, Irene
    Fang, Fang
    Nilsson, Sten
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who had prior or no-prior docetaxel (D) therapy in the phase 3 ALSYMPCA trial
    Koenig, F.
    Vogelzang, N. J.
    Helle, S., I
    Johannessen, D. C.
    O'Sullivan, J. M.
    Garcia-Vargas, J.
    O'Bryan-Tear, C. G.
    Shan, M.
    Parker, C.
    ONKOLOGIE, 2013, 36 : 78 - 78
  • [33] 1.5-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study
    Kuczyk, M.
    Parker, C.
    Vogelzang, N.
    Sartor, O.
    Bottomley, D.
    Coleman, R.
    Skjorestad, I.
    Whaba, M.
    Nilsson, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 178 - 178
  • [34] Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPCA trial
    Vogelzang, Nicholas J.
    Helle, Svein Inge
    Johannessen, Dag Clement
    O'Sullivan, Joe M.
    Garcia-Vargas, Jose E.
    O'Bryan-Tear, C. Gillies
    Shan, Minghua
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] Updated Analysis of Radium-223 Dichloride (Ra-223) Impact on Survival, Safety, and Skeletal-Related Events in Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastases From the Phase 3 ALSYMPCA Trial
    Wedel, S.
    Kranert, T. W.
    Chodacki, A.
    Staudacher, K.
    Garcia-Vargas, J.
    Parker, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S190 - S190
  • [36] PAIN AND QUALITY OF LIFE (QOL) ANALYSES FROM THE PHASE 3 RANDOMIZED ALSYMPCA STUDY WITH RADIUM-223 DICHLORIDE (RA-223) IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS WITH BONE METASTASES
    Tomblyn, Michael
    Nilsson, Sten
    Vogelzang, Nicholas
    Sartor, A. Oliver
    Cislo, Paul
    Van Gool, Renilt
    Aksnes, Anne-Kirsti
    Parker, Chris
    JOURNAL OF UROLOGY, 2013, 189 (04): : E293 - E293
  • [37] Effects of radium-223 dichloride (Ra-223) on total alkaline phosphatase (ALP) and prostate-specific antigen (PSA) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA trial
    Strauss, A.
    Heinrich, D.
    Parker, C.
    Shan, M.
    Wilhelm, S.
    Garcia-Vargas, J.
    O'Bryan-Tear, C. G.
    Sartor, O.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 177 - 178
  • [38] Time to first skeletal-related event (SRE) with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases: ALSYMPCA trial stratification factors analysis
    Coleman, R.
    Fossa, S.
    Chodacki, A.
    Wedel, S.
    Bruland, O.
    Staudacher, K.
    Garcia-Vargas, J.
    Sartor, O.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S688 - S688
  • [39] Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases
    Vogelzang, Nicholas J.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (08) : 809 - 819
  • [40] Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA)
    Vogelzang, Nicholas J.
    Parker, Chris
    Nilsson, Sten
    Coleman, Robert Edward
    O'Bryan-Tear, C. Gillies
    Shan, Minghua
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345